Biomanufacturing has committed to digital twins, autonomous operations and continuous processing, yet the measurement infrastructure these visions depend on has not kept pace. Inline process analytical technology, particularly process Raman spectroscopy, addresses this critical gap by delivering continuous, high-frequency data that matches the dynamics of cell culture and enables meaningful process control.
Biomanufacturing has spent the better part of a decade talking about autonomous facilities, digital twins, continuous bioprocessing, and Pharma 4.0. The vocabulary is settled. The conferences cycle through it reliably. The vendors have aligned their messaging. What remains underbuilt, visibly, is the layer underneath: the measurement infrastructure any of these visions actually depend on.
A digital twin of a bioreactor is not a twin if its inputs arrive on a two-hour sampling cycle. An autonomous feed strategy is not autonomous if its control variables are measured offline. A continuous process is not continuous, in the meaningful sense, if the analytics wrapped around it are batch. These are not pedantic distinctions. They are the difference between a process being modelled and a process being controlled.
The gap is not one of ambition, and it is not one of conviction. Few people working in biomanufacturing would argue that offline assays and manual sampling are the future. The gap is one of investment priority. Modelling, data infrastructure, and control software have all received sustained attention over the last decade. The sensing and measurement layer that feeds them has not kept pace. The result is an industry whose control systems are designed for data they do not yet reliably receive.
Inline process analytical technology, and process Raman spectroscopy in particular, is one of the places that gap gets closed. Raman measures multiple critical process parameters continuously and non-destructively, at frequencies that match the dynamics of a cell culture rather than the cadence of a lab shift. It is not the whole answer. It is the part of the answer most directly aligned with the control ambitions the rest of the industry has already committed to.
The non-trivial work is in the implementation. Chemometric models must be built for the specific process and hold up under the variability real cell cultures produce, clone drift, and bioreactor heterogeneity. The measurement should integrate into control architectures not designed to accept high-frequency inputs. And the robustness case must be made credibly enough that operators, engineers, and regulators will trust a decision made on spectra rather than on a sample sent to the lab.
European Pharmaceutical Review is taking up these questions in an upcoming webinar, ‘Optimising efficiency and yield through bioprocessing automation’. The session covers how process Raman moves perfusion operations toward closed-loop control, the practical considerations in deploying it, and where it translates into measurable yield.
The interesting question about Pharma 4.0 is not the vision. It is the infrastructure being built, or not built, to support it.
No comments yet